JP2009536221A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009536221A5 JP2009536221A5 JP2009510118A JP2009510118A JP2009536221A5 JP 2009536221 A5 JP2009536221 A5 JP 2009536221A5 JP 2009510118 A JP2009510118 A JP 2009510118A JP 2009510118 A JP2009510118 A JP 2009510118A JP 2009536221 A5 JP2009536221 A5 JP 2009536221A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- tetrazole
- conr
- phenyl
- och
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79800106P | 2006-05-05 | 2006-05-05 | |
| US60/798,001 | 2006-05-05 | ||
| PCT/US2007/068342 WO2007131219A2 (en) | 2006-05-05 | 2007-05-07 | Cannabinoid receptor antagonists/inverse agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009536221A JP2009536221A (ja) | 2009-10-08 |
| JP2009536221A5 true JP2009536221A5 (enExample) | 2010-06-24 |
| JP5561720B2 JP5561720B2 (ja) | 2014-07-30 |
Family
ID=38668620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009510118A Expired - Fee Related JP5561720B2 (ja) | 2006-05-05 | 2007-05-07 | 肥満及び糖尿病を含む心臓血管障害を治療するために有用なカンナビノイド受容体アンタゴニスト／インバ−スアゴニスト |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US7482470B2 (enExample) |
| EP (1) | EP2023920B1 (enExample) |
| JP (1) | JP5561720B2 (enExample) |
| CN (1) | CN101484161A (enExample) |
| AU (1) | AU2007247878B2 (enExample) |
| CA (1) | CA2651385C (enExample) |
| ES (1) | ES2389569T3 (enExample) |
| IL (1) | IL195071A (enExample) |
| WO (1) | WO2007131219A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7655685B2 (en) * | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| WO2009085198A2 (en) * | 2007-12-20 | 2009-07-09 | Indigene Pharmaceuticals, Inc. | Combination of metformin r-(+)-lipoate and antiobesity agents for the treatment of diabetic hyperglycemia and diabetic complications |
| EP2242745A1 (de) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8217038B2 (en) | 2009-10-07 | 2012-07-10 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| CA2818198A1 (en) * | 2010-11-18 | 2012-05-24 | Jenrin Discovery | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8680131B2 (en) | 2012-07-25 | 2014-03-25 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers |
| US11155521B2 (en) | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| CA2889697C (en) | 2012-11-13 | 2023-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| CN106660968B (zh) * | 2014-05-09 | 2020-02-07 | 美国政府(由卫生和人类服务部的部长所代表) | 吡唑衍生物及其作为大麻素受体介体的用途 |
| KR20210152312A (ko) | 2020-06-08 | 2021-12-15 | 주식회사 종근당 | 카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물 |
| WO2023089612A1 (en) | 2021-11-19 | 2023-05-25 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Peripheral cb1 receptor antagonists for treatment of lower urinary tract symptoms (luts) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69733154T2 (de) | 1996-02-02 | 2006-03-09 | Merck & Co., Inc. | Verfahren zur behandlung von diabetes und verwandter krankheitszustände. |
| CA2245529A1 (en) | 1996-02-02 | 1997-08-07 | Soumya P. Sahoo | Antidiabetic agents |
| JP2002515865A (ja) | 1996-02-02 | 2002-05-28 | メルク エンド カンパニー インコーポレーテッド | 抗糖尿病薬 |
| WO1997028137A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Heterocyclic derivatives as antidiabetic and antiobesity agents |
| EP1268435B1 (en) | 2000-03-23 | 2006-11-22 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb 1-antagonistic activity |
| JP4313672B2 (ja) * | 2001-09-21 | 2009-08-12 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | 強力なｃｂ１−拮抗活性を有する４，５−ジヒドロ−１ｈ−ピラゾール誘導体 |
| AU2002333852B2 (en) * | 2001-09-21 | 2006-07-13 | Solvay Pharmaceuticals B.V. | Novel 4,5-dihydro-1H-pyrazole derivativeshaving CB1-antagonistic activity |
| US7655685B2 (en) * | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
-
2007
- 2007-05-07 CA CA2651385A patent/CA2651385C/en active Active
- 2007-05-07 ES ES07761946T patent/ES2389569T3/es active Active
- 2007-05-07 US US11/745,162 patent/US7482470B2/en active Active
- 2007-05-07 WO PCT/US2007/068342 patent/WO2007131219A2/en not_active Ceased
- 2007-05-07 JP JP2009510118A patent/JP5561720B2/ja not_active Expired - Fee Related
- 2007-05-07 CN CNA2007800249328A patent/CN101484161A/zh active Pending
- 2007-05-07 EP EP07761946A patent/EP2023920B1/en not_active Not-in-force
- 2007-05-07 AU AU2007247878A patent/AU2007247878B2/en not_active Ceased
-
2008
- 2008-10-14 US US12/250,654 patent/US7666889B2/en active Active
- 2008-11-03 IL IL195071A patent/IL195071A/en active IP Right Grant
-
2010
- 2010-01-12 US US12/685,695 patent/US8088809B2/en not_active Expired - Fee Related
-
2011
- 2011-12-23 US US13/336,733 patent/US20130005784A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009536221A5 (enExample) | ||
| JP2009529540A5 (enExample) | ||
| JP2025037925A5 (enExample) | ||
| JP2010511721A5 (enExample) | ||
| JP2006151984A5 (enExample) | ||
| JP2011520815A5 (enExample) | ||
| JP2018135343A5 (enExample) | ||
| JP2007534702A5 (enExample) | ||
| JP2009504764A5 (enExample) | ||
| JP2005523922A5 (enExample) | ||
| JP2012505871A5 (enExample) | ||
| JP2008510770A5 (enExample) | ||
| JP2010515731A5 (enExample) | ||
| JP2004516314A5 (enExample) | ||
| JP2013510860A5 (enExample) | ||
| JP2012515776A5 (enExample) | ||
| JP2011037841A5 (enExample) | ||
| JP2011522789A5 (enExample) | ||
| JP2010503698A5 (enExample) | ||
| CA2569850A1 (en) | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido [2,3-d] pyrimidine derivatives and related compounds for the treatment of cancer | |
| JP2012006912A5 (ja) | トリアゾール誘導体 | |
| JP2014509612A5 (enExample) | ||
| JP2019529419A5 (enExample) | ||
| JP2015524019A5 (enExample) | ||
| JP2008545631A5 (enExample) |